Cardonilimab
Resectable Clear Cell Carcinoma of the Kidney
The First Hospital of Jilin UniversityPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
23 Active assets in the Resectable Clear Cell Carcinoma of the Kidney cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Everolimus Peking University First Hospital | Phase 2 | BB |
Axitinib University of California, San Francisco | Phase 3 | B |
Nivolumab Exelixis | Phase 2 | B |
gw786034 Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | Phase 2 | B |
MODIFIED VACCINIA VIRUS ANKARA-5T4 ANTIGEN Oxford BioMedica | Phase 3 | B |
View all 39 →
Same molecule, other indications
Cardonilimab is also rated in:
Participants Who Had Received Second-line or Higher Advanced Melanoma and Advanced Renal CancerDormant
NR
Indicative ·
/ 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →